Preclinical research has shown that EphA2-specific CAR-T cells can induce regression of glioma xenografts in severe combined immunodeficiency (SCID) mice and a significant survival advantage compared to untreated mice and mice treated with nontransduced T-cells (186). This evidence concerns the gene EPHA2 and central nervous system cancer.